A case of perioperative euglycemic ketoacidosis in a patient without diabetes: are current guidelines enough?
Abstract
Background: Euglycemic ketoacidosis (eKA) is a serious and potential life-threatening complication of SGLT2-inhibitor (SGLT2i) use. eKA associated with SGLT2i has been increasingly reported in patients without diabetes likely due to more widespread use. The perioperative setting is a particularly vulnerable time for patients due to decreased carbohydrate intake, volume depletion, medication changes, and increased counterregulatory hormone activity due to surgical stress. Current guidelines recommend that patients with type 2 diabetes hold SGLT2i for at least 24-72 h prior to elective surgery.
Case presentation: We report a case of an 82-year-old woman without a history of diabetes who held empagliflozin for 72 h prior to planned bowel resection for management of colon cancer. The indication for empagliflozin was heart failure with reduced ejection fraction. Intraoperatively, she was found to have profound metabolic acidosis, high-normal anion gap, normal glucose, and elevated serum beta hydroxybutyrate. Given the high risk for decompensation intraoperatively, the patient was empirically given dextrose and insulin to treat eKA. The surgery was otherwise uncomplicated. Afterward, the patient was transferred to the intensive care unit for treatment of eKA with insulin and dextrose infusions. She recovered and was discharged home. Empagliflozin was not restarted.
Conclusions: Our patient's case demonstrates that there is not a one-size-fits-all approach to withholding SGLT2i in…
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.